Miami Lakes, FLNCT07505004Now EnrollingIRB Ready

Focal Epilepsy Clinical Trial in Miami Lakes, FL

Access cutting-edge focal epilepsy treatment through this clinical trial at a research site in Miami Lakes. Study-provided care at no cost to qualified participants.

Sponsored by Praxis Precision Medicines

Quick Self-Assessment

See if you qualify for this Miami Lakes location

Preparing your pre-screening questions…

Expert Care in Miami Lakes

Access focal epilepsy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related focal epilepsy treatment provided free

Apply for This Miami Lakes Location

Check if you qualify for this focal epilepsy clinical trial in Miami Lakes, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami Lakes

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami Lakes site if eligible
  4. 4Begin participation

About This Focal Epilepsy Study in Miami Lakes

A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

Sponsor: Praxis Precision Medicines

Who Can Participate

Inclusion Criteria

Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).
Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor.
Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.
Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.
Seizure diary must be completed for ≥80% days in the Observation Period.

Exclusion Criteria

Participant has had any of the following within the 12-month period preceding trial entry:
evidence of experiencing pseudo or psychogenic seizures
cluster seizures where the individual seizures cannot be counted
an episode of convulsive status epilepticus requiring hospitalization and intubation
seizures secondary to illicit drug or alcohol use
Seizures secondary to ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness deemed progressive, progressive structural lesion or encephalopathy.
Previously documented EEG which shows any pattern not consistent with focal etiology of seizures.
Planned epilepsy surgery during the course of the clinical trial.
History of any of the following:
neurosurgery for seizures \<1 year prior to enrollment
radiosurgery \<2 years prior to enrollment
neurostimulator placed \<1 year prior to Screening
neurostimulator placed \>1 year prior to Screening but settings have not been stable for at least 2 months prior to Screening
Active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt, as confirmed by C-SSRS.
Has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or ongoing or recent history of any psychiatric, medical, or surgical condition.
Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 3 years are excluded.
History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities.
Total bilirubin value \>1.5×ULN; an ALT or AST value \>3×ULN.
History of or active HIV infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection, as determined by relevant screening assessments.
Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene or cell therapy.
Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.
Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to screening.
Significant allergic reaction to an ASM(s), including dermatological (e.g. Stevens-Johnson syndrome), hematological, or organ toxicity reactions. Severe reactions do not include simple maculopapular eruption and allergic rhinitis.
Is pregnant or breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or prior to end of study visit.
Previous exposure to vormatrigine or known hypersensitivity to any component used in the vormatrigine formulation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami Lakes?

Yes, this clinical trial (NCT07505004) has an active research site in Miami Lakes, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Focal Epilepsy Treatment Options in Miami Lakes, FL

If you're searching for focal epilepsy treatment options in Miami Lakes, FL, this clinical trial (NCT07505004) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami Lakes research site is actively enrolling participants for this clinical trial. You'll receive care from experienced focal epilepsy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all focal epilepsy clinical trials near you to find additional studies recruiting in your area.

More Epilepsy Trials in Miami Lakes, FL

See all epilepsy clinical trials recruiting in Miami Lakes — not just this study.

Browse Epilepsy Trials in Miami Lakes →

Browse More Trials by Condition

Epilepsy TrialsTemporal Lobe Epilepsy TrialsAll Conditions →

Ready to Join in Miami Lakes?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami Lakes, FL